B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases

Bratislava Medical Journal

Volumn 110, Issue 3, 2009, Pages 137-145

  Krivosikova, M ^a   Dallos, T ^b   Maslinski, W ^c   Buc, M ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b University Children's Hospital   (Slovakia)

^c INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Autoimmunity; B cells; BAFF

Indexed keywords

B CELL ACTIVATING FACTOR;

ANIMAL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; HUMANS;

EID: 70349769212     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Buc M. Autoimmunity. 205-217. In: Buc M (Ed). Basic and clinical immunology. Bratislava; Comenius University Press, 2008.
2. Sutherland AP et al. Targeting BAFF: immunomodulation for auto immune diseases and lymphomas. Pharmacol Ther 2006; 112 (3): 774-786.
3. Schiemann B et al. An essential role for BAFF in the normal deve lopment of B cells through a BCMA-independent pathway. Science 2001; 293 (5537): 2111-2114.
4. Rahman ZS et al. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003; 198 (8): 1157-1169.
5. Gorelik L et al. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004; 172 (2): 762-766.
6. Baker KP. BLyS-an essential survival factor for B cells: basic biolo gy, links to pathology and therapeutic target. Autoimmun Rev 2004; 3 (5): 368-375.
7. Sasaki Y et al. TNF family member B cell-activating factor (BAFF) receptor-dependent and-independent roles for BAFF in B cell physiolo gy. J Immunol 2004; 173 (4): 2245-2252.
8. Ng LG et al. The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 2005; 42 (7): 763-772.
9. Seyler TM et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115 (11): 3083-3092.
10. Vallerskog T et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rhe umatoid arthritis. Arthritis Res Ther 2006; 8 (6): 167.
11. Bodmer JL et al. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27: 19-26.
12. Melchers F. Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 2003; 62 (2): 25-27.
13. Tribouley C et al. Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem 1999; 380: 1443-1447.
14. Nardelli B et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2000; 97: 198-204.
15. Litinskiy MB et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-829.
16. Scapini P et al. G-CSF-stimulated neutrophils are a prominent sour ce of functional BLyS. J Exp Med 2003; 197: 297-302.
17. Gavin AL et al. DeltaBAFF, an alternate splice isoform that regula tes receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003; 278: 38220-38228.
18. Gavin AL et al. DeltaBAFF, a splice isoform of BAFF, opposes fulllength BAFF activity in vivo in transgenic mouse models. J Immu nol 2005; 175:319-328.
19. Roschke V et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-4321.
20. Dejardin E et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17: 525-535.
21. Lesley R et al. Reduced competitiveness of autoantigen-engaged B ce lls due to increased dependence on BAFF. Immunity 2004; 20: 441-453.
22. Schneider P et al. BAFF, a novel ligand of the tumor necrosis factor (TNF) family, stimulates B cell growth. J Exp Med 1999;189: 1747-1756.
23. Moore PA et al. BlyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.
24. Huard B et al. BAFF production by antigen-presenting cells provi des T cell costimulation. Int Immunol 2004; 16: 467-475.
25. Ogden CA et al. Enhanced apoptotic cell clearance capacity and b cell survival factor production by IL-10-activated macrophages: impli cations for burkitt's lymphoma. J Immunol 2005; 174: 3015-3023.
26. Scapini P et al. Proinflammatory mediators elicit the secretion of the intracellular B-lymphocyte stimulator (BLyS) pool that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2004; 105: 830-837.
27. Assi LK et al. Tumor necrosis factor a activates release of B lym phocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis & rheumatism 2007; 56 (6): 1776-1786.
28. Mackay F, Tangye SG. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 2004; 4: 347-354.
29. Krumbholz M et al. BAFF is produced by astrocytes and upregu lated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201: 195-200.
30. Ohata J et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in respon se to proinflammatory cytokines. J Immunol 2005; 174: 864-870.
31. Gorelik L et al. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003; 198:937-945.
32. Mackay F, Mackay CR. The role of BAFF in B cell maturation. Tcell activation and autoimmunity. Trends Immunol 2002; 23: 113-115.
33. Mackay F et al. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007; 19 (3): 327-336.
34. Krivošíková M et al. Mesenchymal stromal cells from bone mar row of rheumatoid arthritis patients provide survival signals to B cells in vitro. Ann Rheum Dis 2007; 66 (Suppl II): 292.
35. Thompson JS et al. BAFF-R, a novel TNF receptor that specifical ly interacts with BAFF. Science 2001; 293: 2108-2111.
36. Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 2003; 14: 311-324.
37. Hsu BL et al. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002; 168: 5993-5996.
38. Cancro MP. Peripheral B cell maturation: the intersection of selection and homeostasis. Immunol Rev 2004; 197: 89-101.
39. Avery DT et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 286-297.
40. Ng LG et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173: 807-817.
41. Cancro MP. The BLyS family of ligands and receptors: an archety pe for nichespecific homeostatic regulation. Immunol Rev 2004; 202: 237-249.
42. Von Bulow GU, Bram RJ. NF-ATactivation induced by a CAMLinteracting member of the tumor necrosis factor receptor superfamily. Science 1997; 278: 138-141.
43. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2: 465-475.
44. Mackay F et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21: 231-264.
45. He B et al. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004; 173: 4479-4491.
46. Batten M et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192: 1453-1465.
47. Huard B et al. T cell costimulation by the TNF ligand BAFF. J Immunol 2001; 167: 6225-6231.
48. Sutherland APR et al. BAFF augments certain Thl-associated in flammatory responses. J Immunol 2005; 174: 5537-5544.
49. Wang H et al. TACI-ligand interactions are required for T cell activation and collagen induced arthritis in mice. Nat Immunol 2001; 2: 632-637.
50. Ye Q et al. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 2004; 34: 27-50.
51. Khare SD et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenicmice. ProcNatl Acad Sci USA 2000; 97:3370-3375.
52. Mackay F et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190: 1697-1710.
53. Yan M et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficien cy. Curr Biol 2001; 11: 1547-1552.
54. Gross JA et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
55. Benson MJ et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180 (6): 3655-3659.
56. Miller DJ, Hayes CE. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur J Immu nol 1991; 21: 1123-1130.
57. Shulga-Morskaya S et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004; 173:2331-2341.
58. von Bulow GU et al. Regulation of the T-independent humoral res ponse by TACI. Immunity 2001; 14: 573-582.
59. Yan M et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001; 2: 638-643.
60. Seshasayee D et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18: 279-288.
61. Castigli E et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005; 201: 35-39.
62. Castigli E et al. TACI is mutant in common variable immunodefi ciency and IgA deficiency. Nat Genet 2005; 37: 829-834.
63. Salzer U et al. Mutations in TNFRSF13B encoding TACI are asso ciated with common variable immunodeficiency in humans. Nat Genet 2005; 37: 820-828.
64. Xu S, Lam KP. B cell maturation protein, which binds the Tumor Necrosis Factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001; 21: 4067-4074.
65. O'Connor BP et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91-98.
66. Yang M et al. B cell maturation antigen, the receptor for a proliferationinducing ligand and B cell-activating factor of the TNF family, in duces antigen presentation in B cells. J Immunol 2005; 175: 2814-2824.
67. Gross JA et al. TACI and BCMA are receptors for a TNF homologue implicated in B cell autoimmune disease. Nature 2000; 404: 995-999.
68. Zhang M et al. Expression and function of TNF family member B cell activating factor in the development of autoimmune arthritis. Int Immunol 2005; 17: 1081-1092.
69. Zheng Y et al. A role for B cell-activating factor of the TNF family in chemically induced autoimmunity. J Immunol 2005; 175:6163-6168.
70. Stohl W et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2080-2091.
71. Jiang Y et al. Polymorphism and chromosomal mapping of the mouse gene for B cell activating factor belonging to the tumor necrosis factor family (Baff) and association with autoimmune phenotype. Immunogenetics 2001; 53: 810-813.
72. Kawasaki A et al. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3: 424-429.
73. Gottenberg JE et al. No evidence for an association between the-871 T/C promoter polymorphism in the B cell-activating factor gene and primary Sjogren's syndrome. Arthritis Res Ther 2006; 8: 30.
74. Krumbholz M et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005; 25: 298-302.
75. Batten M et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004; 172: 812-822.
76. Groom J et al. Association of BAFF/BLyS overexpression and alte red B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109: 59-68.
77. Stohl W et al. B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol 2002;104: 115-122.
78. Boule MW et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004; 199: 1631-1640.
79. Edwards JC, Cambridge G. Sustained improvement in rheumato id arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001; 40: 205-211.
80. Eisenberg R. SLE-Rituximab in lupus. Arthritis Res Ther 2003; 5: 157-159.
81. Gorman C et al. B cell depletion in autoimmune disease. Arthritis Res Ther 2003; 5(4): 17-21.
82. Oligino TJ, Dalrymple SA. Targeting B cells for the treatment of rheumatoid arthritis. Arthritis Res Ther 2003; 5(4): 7-11.
83. Edwards JC et al. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
84. Ramanujam M, Davidson A. The current status of targeting BAFF/BLys for autoimmune diseases, Arthritis Res Ther 2004; 6: 197-202.
85. Liu W et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus encoded soluble TACI. Arthritis Rheum 2004; 50: 1884-1896.
86. Chan OTM et al. A novel mouse with B cells lacking serum antibo dy reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-1647.
87. Shlomchik MJ et al. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147-153.
88. Takemura S et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167: 1072-1080.
89. Takemura S et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167: 4710-4718.
90. Weyland CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann NY Acad Sci 2003; 987: 140-149.
91. Dunussi-Joannopoulos K et al. B cell depletion inhibits arthritis in a collagen induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 2005; 106: 2235-2243.
92. O'Neill SK et al. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 2005; 174: 3781-3788.